The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 23273606 |
64 |
Design, synthesis, and structure-activity relationships of a series of 4-benzyl-5-isopropyl-1H-pyrazol-3-ylß-D-glycopyranosides substituted with novel hydrophilic groups as highly potent inhibitors of sodium glucose co-transporter 1 (SGLT1). |
Kissei Pharmaceutical |
| 23062824 |
72 |
Structure-activity relationship studies of 4-benzyl-1H-pyrazol-3-ylß-d-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia. |
Kissei Pharmaceutical |
| 19243175 |
13 |
Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2. |
Bristol-Myers Squibb |
| 21565497 |
38 |
Optimization of triazoles as novel and potent nonphlorizin SGLT2 inhibitors. |
Amgen |
| 21449606 |
15 |
Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. |
Pfizer |
| 21398124 |
62 |
Discovery of non-glucoside SGLT2 inhibitors. |
Amgen |
| 30268701 |
25 |
Design, synthesis and biological evaluation of (2S,3R,4R,5S,6R)-5-fluoro-6-(hydroxymethyl)-2-aryltetrahydro-2H-pyran-3,4-diols as potent and orally active SGLT dual inhibitors. |
Janssen Research & Development |
Search and Browse
